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Abstract
Motivation: While high-throughput sequencing (HTS) has been used successfully to discover
tumor-specific mutant peptides (neoantigens) from somatic missense mutations, the field currently
lacks a method for identifying which gene fusions may generate neoantigens.
Results: We demonstrate the application of our gene fusion neoantigen discovery pipeline, called
INTEGRATE-Neo, by identifying gene fusions in prostate cancers that may produce neoantigens.
Availability and Implementation: INTEGRATE-Neo is implemented in Cþþ and Python. Full source
code and installation instructions are freely available from https://github.com/ChrisMaherLab/
INTEGRATE-Neo.
Contact: christophermaher@wustl.edu
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The mutational landscape of cancer genomes results in the produc-
tion of tumor specific peptides recognizable by immune molecules.
These so-called neoantigens can be exploited for personalized cancer
immunotherapy (Heemskerk et al., 2013). To date, multiple studies
have successfully used Next Generation Sequencing (NGS) to dis-
cover tumor specific neoantigens (Carreno et al., 2015; Gubin et al.,
2014; Matsushita et al., 2012). These analyses have relied on som-
atic missense mutation-based neoantigen discovery workflows like
pVAC-Seq (Hundal et al., 2016). Despite these successes, such meth-
ods do not consider gene fusions, which occur when two genes are
rearranged in the genome to encode an aberrant transcript that
may translate into a novel immunogenic peptide. To address this
critical gap, we developed the first open source pipeline, called
INTEGRATE-Neo, for gene fusion neoantigen discovery using NGS
data. INTEGRATE-Neo expands the functionality of our highly ac-
curate gene fusion discovery tool, INTEGRATE (Zhang et al.,
2016). Here, we apply INTEGRATE-Neo to the TCGA prostate co-
hort data (PRAD) to demonstrate its utility for identifying gene
fusion neoantigens that may serve as personalized cancer immuno-
therapy targets.
2 The INTEGRATE-neo pipeline
The gene fusion neoantigen discovery pipeline, INTEGRATE-Neo,
is comprised of the following steps: (1) gene fusion peptide predic-
tion, (2) HLA allele prediction and (3) gene fusion neoantigen dis-
covery (Fig. 1).
The first step takes (1) the human reference genome in FASTA
format, (2) gene models in GenePred format and (3) gene fusions in
BEDPE format predicted by INTEGRATE as input to predict gene
fusion peptides. The BEDPE follows the standards provided by The
ICGC-TCGA DREAM Somatic Mutation Calling-RNA Challenge
(SMC-RNA). This step annotates the gene fusion predictions with
information such as gene fusion exonic boundaries, open reading
frames (ORF), and the predicted peptide at the fusion junction. Each
codon within the 50 gene partner is inferred according to the starting
position of the 50 ORF. The amino acids spanning the fusion
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junction are determined by the codons that result from merging the
sequences of both the 50 and 30 gene partners. The 30 reading frames,
which may have shifted, are then calculated for the remaining por-
tion of the gene fusion transcript downstream of the fusion junction
until a stop codon is encountered. These annotations are appended
as user defined columns to the BEDPE file. Gene fusions that do not
produce a predicted fusion peptide are subsequently filtered.
The second step takes (1) high-throughput sequencing reads in
FASTQ format and (2) reference HLA alleles in FASTA format as in-
put to predict HLA alleles. It performs alignment using BWA (Li and
Durbin, 2009) and predicts the HLA alleles using HLAminer v 1.3
(Warren et al., 2012). This module outputs a Tab-separated value
(TSV) file for the predicted HLA alleles that includes the four-digit
HLA allele names, scoring metrics from HLAminer (score, e-value
and confidence), and the prediction source. To increase the flexibility
of INTEGRATE-Neo, a user has the option to upload their own HLA
alleles in case they use another method, such as sequence-specific
oligonucleotide probe hybridization and serotyping techniques, or al-
ready have algorithmic predicted results for their dataset.
The third neoantigen discovery step takes in (1) a TSV file for
the predicted HLA alleles, (2) an annotated BEDPE file for the pre-
dicted gene fusion peptides and (3) a file of the list of HLA alleles
supported by NetMHC v 4.0 (Andreatta and Nielsen, 2016). The
epitope lengths supplied are 8–11 by default but can be defined by
the user. For each epitope length, a FASTA file is prepared with pep-
tides of 2n  1 amino acids, where n is the epitope length set by
‘l’. The single amino acid in the middle spans the fusion junction.
If the 50 junction is at a full codon, then a peptide of 2n  2 amino
acids is used. If a non-coding region (UTR) is encountered, the pep-
tide sequence can be shorter than 2n  1 (or 2n  2). The summar-
ization module keeps the epitope with the highest predicted binding
affinity (nM) passed a user-defined threshold (default: 500) for each
neoantigen. The final result is a BEDPE file with gene fusion neoan-
tigen predictions. The summarization module appends the epitope
sequences, binding affinities, HLA alleles and metrics of the HLA al-
leles, as user defined columns, to the output BEDPE file.
To ensure user-friendliness, all of the modules within INTEGRATE-
Neo are designed as standalone tools with their own optional param-
eters. This enables users to incorporate INTEGRATE-Neo functions
within their existing pipelines. INTEGRATE-Neo also ensures that all
the modules are running the same version of the software. The paths to
software and databases can be set in setup.ini.
3 Application to TCGA PRAD cohort
RNA-seq reads of 333 TCGA PRAD tumor samples were used to dis-
cover gene fusions and gene fusion neoantigens using INTEGRATE
and INTEGRATE-Neo (Supplementary Methods). We discovered
1761 gene fusions in the 333 prostate cancer samples that generate
2707 fusion transcript isoforms (Supplementary Table S1). 2369 (87.
5%) of the 2707 fusion transcripts have canonical exon boundaries,
and 338 (12.5%) have junctions in other (non-exonic or truncated
exonic) regions. 61 (3.5%) of the 1761 gene fusions are recurrent
(occur in2 patients; Supplementary Table S2; Supplementary Figs.
S1 and S2) and 1700 (96.5%) are singletons (occur in 1 patient).
INTEGRATE-Neo predicted 1600 (1300 singleton and 300 recurrent)
fusion junction peptides for the 2,707 gene fusion transcripts. Of
these, 240 (15%) (Supplementary Fig. S3a and Table S3) have epi-
topes with binding affinity scores500 nM. The epitopes encom-
passed all epitope lengths as follows: 2.7%, 60.8%, 33.7% and 2.7%
for 8, 9, 10 and 11 amino acids, respectively (Supplementary Fig.
S3b). Interestingly, binding affinity scores skewed towards 1 rather
than 500, with smaller scores indicating better binding affinities
(Supplementary Fig. S3c). This pattern was consistent across all epi-
tope lengths (Supplementary Fig. S3d). The most frequent gene fusion
neoantigen from TMPRSS2-ERG is shown in Supplementary Figure
S4. Epitope affinities in different HLA alleles and in recurrent gene fu-
sions are shown in Supplementary Figure S5.
Analysis of the TCGA PRAD data with the aforementioned par-
ameters on our servers with 2.50 GHz Intel Xeon processors had an
average runtime of 75.16 29.2 seconds and average memory usage
of 1.886 0.90 GB per patient using single thread highlighting the ef-
ficiency of INTEGRATE-Neo (Supplementary Fig. S6).
4 Discussion
Here, we described the first automated gene fusion neoantigen dis-
covery pipeline, INTEGRATE-Neo, and demonstrated that it can ef-
ficiently process the TCGA prostate cancer patient cohort. This
revealed predicted gene fusions neoantigens across a distribution of
epitope binding affinities. Overall, INTEGRATE-Neo provides a
valuable resource to the cancer community by complementing exist-
ing somatic missense mutation-based neoantigen discovery methods
to ensure that no potential neoantigen is missed in the search for
personalized immunotherapy targets.
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